Skip to main content

Table 3 Univariable and multivariable Cox proportional hazard regression analyses of event-free survival

From: Impact of chemotherapy cycles and intervals on outcomes of nonspinal Ewing sarcoma in adults: a real-world experience

FactorUnivariable analysisPMultivariable analysisP
HR (95%CI)HR (95% CI)
Gender
 MaleReference 
 Female1.107 (0.614–1.993)0.735 
Age at diagnosis
 < 30yReference 
 ≥ 30 y1.410(0.820–2.426)0.215 
Primary site
 ExtremityReference  
 Trunk0.874 (0.500–1.526)0.635
Tumor origin
 SkeletalReference  
 Extraskeletal0.771 (0.418–1.421)0.404
Stage
 LocalizedReference Reference 
 Metastatic1.644 (0.958–2.282)0.0711.743 (1.012–3.002)0.045
Diameter of primary tumor
 < 8 cmReference 
 ≥ 8 cm0.800 (0.458–1.398)0.434 
Local therapy
 SurgeryReference 
 Radiotherapy1.504 (0.733–3.087)0.266 
 Surgery + radiotherapy1.494 (0.806–2.771)0.202
Time to local therapy0.899 (0.732–1.104)0.309
Number of chemotherapy cycles
 < 12Reference Reference0.037
 ≥ 120.592 (0.344–1.017)0.0580.558 (0.323–0.965) 
Frequency of chemotherapy delays
 ≥ 25%Reference 
 < 25%0.739 (0.380–1.439)0.374 
Grade 3–4 chemotherapy toxicity
 YESReference 
 NO0.382(0.053–2.778)0.342 
Administration of dexrazoxane
 YESReference 
 NO1.057(0.616–1.814)0.840 
  1. HR Hazard ratio, CI Confidence interval
\